Biography
Anura David is a medical scientist and PhD student focused on developing molecular technologies for TB diagnosis in resource-limited settings. With over 15 years of experience in clinical validation and TB/HIV studies, she contributed to South Africa’s evaluations of Xpert MTB/RIF, Ultra, BD MAX MDR-TB, and cobas MTB, helping inform national policy. Her work supports pre-market development of diagnostics that improve patient care. Anura also plays a key role in molecular EQA programs using dried culture spot technology, supporting quality and reliability in TB testing across the diagnostic value chain.
Key Impacts
Evaluation of the STANDARD M10 MTB-RIF/INH assay: A rapid solution for drug-resistant TB detection
Preliminary results on the STANDARD M10 MTB-RIF/INH assay demonstrated high diagnostic accuracy. With its ability to detect resistance RIF and INH in a single test, the assay has the potential to enhance treatment decision-making, reduce diagnostic delays, and support global efforts in TB control and resistance surveillance.
Source: Conference 2024
Strengthening TB diagnosis: Integrating new molecular platforms into South Africa’s National TB Programme
The diversification of the TB Molecular Programme has enhanced diagnostic capacity, improved drug resistance detection, and aims to strengthen TB management within the national healthcare system. Diversification requires change management to provide a structured approach for adapting new technologies, processes, and workflows to ensure smooth transitions.
Source: Conference 2024